Bristol changes tack in Claudin18.2
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
Zepzelca’s pivotal surprise
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
